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Abstract.
Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-
motor symptoms of Parkinson’s disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of
safinamide in routine clinical practice, as recommended by the European Medicines Agency.
Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions.
Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients
were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant
comorbidities and with psychiatric conditions.
Results: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8%
with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse
events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were
those already described in the patients’ information leaflet. The majority were mild or moderate and completely resolved and
no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS
motor score and in the UPDRS total score in ≥40% of patients, according to the criteria developed by Shulman et al.
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Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor
complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.
Keywords: Parkinson’s disease, safinamide, MAO-B inhibitor, real-life evaluation
INTRODUCTION
Parkinson’s disease (PD) is the second most com-
mon neurodegenerative illness following Alzhei-
mer’s disease, characterized by the loss of neuro-
melanin—containing neurons in the substantia nigra.
Approximately 1.2 million people live with PD
throughout Europe and the number is expected to
double in the next 10 years [1].
The main motor symptoms of PD are resting
tremor, bradykinesia and rigidity. The disease is
also associated with non–motor symptoms such as
depression, apathy, sleep disorders, pain and gastroin-
testinal disturbances, with a considerable reduction
of patients’ quality of life [2]. The current pharmaco-
logical management is largely based on symptomatic
drugs. Traditional pharmacotherapies for PD aim
to restore depleted dopamine levels in the brain
but are limited by long-term complications, such
as motor fluctuations and dyskinesia. Moreover, the
existing medications usually do not alleviate non-
motor symptoms [3]. Other neurotransmitters beyond
dopamine, in particular glutamate, are believed to
play important roles in the pathogenesis of primary
symptoms, motor fluctuations, dyskinesia and possi-
bly neuronal cell loss [4].
Safinamide is a multimodal drug with a dual mech-
anism of action, dopaminergic (reversible mono-
amine oxidase-B inhibition) and non-dopaminergic
(modulation of the abnormal glutamate release), that
offers an innovative approach to the management of
motor and non-motor symptoms and motor compli-
cations [5]. None of the drugs for PD already on
the market have this peculiar double mechanism of
action, therefore the Movement Disorder Society has
included safinamide in a class of drugs different from
selegiline and rasagiline [6].
Despite that the international guidelines recom-
mend double-blind, placebo or active-controlled
studies to assess the efficacy and safety of a new ther-
apeutic treatment, they do not provide information
on the “real-word” clinical use of these drugs. Many
regulatory authorities are thus encouraging the gener-
ation of “real-world data” that offer the possibility to
derive novel insights on the use and performance of
medicines in everyday clinical use, complementing
with evidence from randomized control trials [7].
During the initial marketing authorization pro-
cedure, the European Medicines Agency (EMA)
recommended to provide additional real-world data
on safinamide treatment in some categories of
patients not well represented in clinical trials, namely
those aged >75, with relevant comorbidities and
with concomitant psychiatric conditions such as
psychosis, bipolar disorder and severe depression.
Following this request, a Drug Utilization Study
(DUS) called “SYNAPSES” (“european multicen-
ter retrospective-prospective cohort StudY to observe
safiNAmide safety profile and pattern of use in clini-
cal Practice during the firSt post-commErcialization
phaSe”) was designed to investigate how safinamide
is prescribed and used in routine clinical practice
and to collect safety data. The aim of the study was




SYNAPSES (EU PAS Register Number EUPAS-
13745) is a multinational, multicenter, retrospective-
prospective cohort observational study. The study
design was conceived to include potentially all
patients treated with safinamide as per clinical prac-
tice. The prospective observation was chosen because
in most countries the study onset was expected to
coincide with the drug commercialization, while the
retrospective part was performed to include also
patients starting treatment before the study onset. The
countries involved were Belgium, Germany, Italy,
Spain, Switzerland and United Kingdom. The study
was conducted in 128 neurology and geriatric centers,
specialized in PD treatment. Physicians participating
in the study got an appropriate compensation.
Both the protocol and patient materials were
approved by Independent Ethics Committees and
Health Authorities in all the participating countries
and the study was conducted according to the eth-
ical standards of the institutional and/or national
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research committee and according to the Declaration
of Helsinki.
A total of 1,610 patients were enrolled. This study
avoided any selection of patients by means of broad
inclusion/exclusion criteria in order to observe the
largest population of patients treated with safinamide.
Patients were eligible provided they met the follow-
ing inclusion criteria: male and female patients aged
≥18 years who started treatment with safinamide at
the enrolment visit or in the previous four months
according to clinical practice, with signed informed
and privacy consent forms. Patients were excluded
if they were participating in any clinical trial with
safinamide at study inclusion. The criteria were more
compelling in Germany due to local Health Author-
ity requirements: in compliance with §67 section 6
AMG (German Drug Law) only patients with con-
firmed diagnosis of PD for whom safinamide was
prescribed in accordance with its summary of product
characteristics (SmPC) were included, while patients
cannot be enrolled in case of contraindications to safi-
namide as listed in safinamide SmPC. According to
the non-interventional study type, the treating physi-
cians were not given any guidelines regarding patient
selection and treatment administration and no random
procedure was applied. Investigators were asked only
to enroll patients in the study consecutively, accord-
ing to the inclusion/exclusion criteria, provided they
were using safinamide in their clinical practice. This
was an observational study, hence the physician’s
decision of starting treatment with safinamide must
be taken before the patient’s inclusion in the study
and was completely independent from the study
protocol.
As for inclusion criteria, adult patients giving their
consent to participate in the study were eligible if they
start treatment at the enrolment visit or in the previous
four months according to clinical practice. This limit
was set in order to allow a reasonable time point for
which data are retrospectively collected, leading to
the exclusion of a negligible number of patients. All
patients were followed for 12 months after the start
of treatment. If a patient discontinued treatment with
safinamide during the study, the observation contin-
ued. Data at baseline (treatment start) and 4, 8, and 12
months after baseline were recorded. Data of patients
enrolled at the start of treatment were prospectively
collected. Otherwise, data of patients enrolled after
the start of treatment were partially retrospective and
updated in continuum during the course of the study.
The primary objective of the study was to describe
the occurrence of adverse events (AEs) in patients
treated with safinamide in real-life conditions for up
to one year. The analysis was conducted overall and
in the targeted subgroups, namely in patients aged
>75, those with relevant comorbidities and those with
psychiatric conditions.
The secondary objectives were to describe the
characteristics of patients treated with safinamide
according to clinical practice and to describe safi-
namide treatment patterns in real-life settings.
Data source and measurements
Investigators were asked to record the data in elec-
tronic standardized case report forms (eCRFs). Given
the observational nature of the study all activities
concerning patient management were conducted in
compliance with the clinical practice of each center.
For all patients enrolled in the study after the sig-
nature of the Informed Consent, data on treatments
and on safety outcomes were prospectively recorded
by the Investigator both by retrieving those already
available from the medical charts and by interview-
ing the patient. For patients starting treatment with
safinamide before the enrolment visit, data were col-
lected retrospectively from each patient’s medical
charts at the moment of the enrolment in the study;
they were later integrated/updated with information
routinely collected interviewing the patient at each
subsequent study visit.
The assessments were made in compliance with
Good Pharmacoepidemiology Practices and with
regulatory and institutional requirements for the pro-
tection of confidentiality of patients. Personal data
were collected, stored and processed exclusively in
pseudonymized form. The eCRF used for the study
was validated according to Good Automated Manu-
facturing Practice version 5 (GAMP5) [8].
Patients were also evaluated with the Unified
Parkinson’s Disease Rating Scale (UPDRS) during
ON time, measuring the changes from baseline to
each follow-up visit in the UPDRS total score and
in the UPDRS part III score. The UPDRS [9] was
chosen because it is widely known and is the rat-
ing scale most commonly used in clinical studies and
in routine clinical practice to follow the longitudinal
clinical course of PD.
Statistical methods
The statistical analysis was done on all “evalu-
able patients for the Full Analysis Set” defined as
the patients satisfying all inclusion criteria and not
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violating any exclusion criteria. All study endpoints
were provided using descriptive statistics. In fact,
the aim of the study was merely descriptive and
there were no pre-specified hypotheses. Categorical
variables were described by means of absolute and
relative frequencies, while continuous variables by
means of mean, standard deviation, quartiles, min and
max. Data collected on all patients were pooled for
statistical analyses. Stratifications by country were
not foreseen because no differences among countries
were detected. Patients with missing values were not
excluded from the analysis, but their data were not
replaced; frequency of missing data was given for
all analyzed variables. However, in order to evaluate
the potential impact of recall bias on the primary end-
point, the proportion of patients experiencing any AE
was provided as sensitivity analysis.
Primary objective of the study
The number of patients with AEs (portion of
patients experiencing at least one AE from the start
of treatment with safinamide until the end of the
observation period), serious adverse events (SAEs)
and adverse drug reactions (ADRs) related to safi-
namide, serious or not, were described. The analyses
were provided overall and for subgroups of interest:
patients aged >75, those with relevant comorbidities
and those concomitantly suffering from psychiatric
conditions. The concomitant relevant comorbidities
(including psychiatric conditions) were those con-
sidered by the study Investigators, based only on
their own clinical judgement, as clinically significant
and/or causing a significant deterioration of patients’
conditions or interfering with PD treatment. Serious-
ness, severity, relation with safinamide according to
Investigator judgment, action taken and outcome of
the event were also summarized. Adverse Event terms
(AEs, SAEs, and ADRs) were coded with the Medi-
cal Dictionary for Regulatory Activities (MedDRA)
version 21.1 [10]. Coding was performed at the end
of the study and periodically during data collection.
Any AE typed in a language different from the one
used for encoding (English) was translated and then
encoded. At the end of data collection 100% of AEs
were reconciled with the Sponsor’s safety database.
Secondary objectives of the study
The following endpoints were evaluated:
• Description of demographic and clinical base-
line characteristics.
• Description of safinamide treatment duration,
including safinamide dose adjustments, inter-
ruptions, discontinuation and episodes of over-
dose.
• Description of changes in other concomitant PD
therapies.
• Motor evaluation, as measured by UPDRS III
(UPDRS scores was summarized at each time
point).
A total of 1,600 patients were expected to be
enrolled in the study. This sample size was defined
based on safety data available from pivotal clinical
trials, where about 66% of patients experienced treat-
ment emergent AEs after 6 months of treatment. With
a 20% drop-out rate, 1280 evaluable patients allow to
observe the same proportion rate of AEs with a 95%
confidence interval between 63% and 68%.
Study results were clinically reviewed and valued
by the Study Outcome Review Board. SAS for Win-
dows Version 9.4 and SAS Enterprise Guide 7.1 were




The patients’ overview is shown in Table 1. Out of
the 1610 patients enrolled in the SYNAPSES study,
1,558 (96.8%) were evaluable for the analysis, with
more than 80% followed up prospectively for one
year.
Overall, 37.1% of patients had Hoehn and Yahr
(H&Y) stage >2 [11]. Lower H&Y stages were
observed for younger patients (vs older ones), for
patients without (vs patients with) relevant comor-
bidities and for patients without (vs patients with)
psychiatric conditions.
Motor symptoms were reported for 1,151 (99.6%)
patients (this information was missing for the remain-
ing 7 patients) and about 88% of subjects had also
non-motor symptoms. Tremor and postural instabil-
ity were more frequent in older patients and in patient
with comorbidities, while postural instability and
rigidity were preeminent in patients with psychiatric
conditions.
Regarding non-motor symptoms, older patients
showed a higher frequency of cognitive, cardiovas-
cular, gastrointestinal and urinary symptoms than
younger patients. Sleep disorders, psychiatric and
cognitive symptoms, fatigue and pain were more
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Table 1
Patients’ overview
FAS Patients Patients with Patients with
(N = 1,558) aged > 75 y relevant psychiatric
(N = 391) comorbidities conditions
(N = 1,103) (N = 661)
Gender (N, %) Male 961 (61.7%) 221 (56.5%) 665 (60.3%) 356 (53.9%)
Female 597 (38.3%) 170 (43.5%) 438 (39.7%) 305 (46.1%)
Age at enrolment (y) Mean (SD) 68.4 (9.7) 79.7 (3.1) 70.0 (8.7) 68.3 (9.4)
Race (N, %) Caucasian 1,543 (99.0%) 389 (99.5%) 1094 (99.2%) 658 (99.5%)
Other 15 (1.0%) 2 (0.5%) 9 (0.8%) 3 (0.5%)
Diagnosis (N, %) Idiopathic PD 1,542 (99.0%) 389 (99.5%) 1094 (99.2%) 653 (98.8%)
Atypical Parkinsonisms 12 (0.8%) 2 (0.5%) 7 (0.6%) 6 (0.9%)
Other∗ 4 (0.2%) 0 (0.0%) 2 (0.2%) 2 (0.3%)
Time from PD diagnosis (y): mean (SD) 7.9 (5.3) 7.9 (5.3) 7.8 (5.3) 8.4 (5.5)
Time from PD onset of symptoms (y):
mean (SD)
8.8 (5.5) 8.9 (5.5) 8.7 (5.4) 9.3 (5.5)
Age at onset of symptoms (y): mean (SD) 59.3 (11.0) 70.9 (6.5) 61.0 (10.1) 58.8 (10.7)
Hoehn & Yahr stage 1 92 (5.9%) 6 (1.5%) 50 (4.5%) 22 (3.4%)
2 888 (57.0%) 167 (42.5%) 610 (55.3%) 332 (50,4%)
3 473 (30.3%) 167 (42.9%) 361 (32.7%) 234 (35.2%)
4 99 (6.4%) 46 (11.9%) 77 (7.0%) 68 (10.3%)
5 6 (0,4%) 5 (1.2%) 5 (0.5%) 5 (0.7%)
Percentages (%) were computed by column. FAS, Full Analysis Set; N, number of patients; SD, standard deviation; PD, Parkinson’s disease.
∗Patients with other diagnosis had juvenile Parkinson’s disease.
frequent in patients with comorbidities and those with
psychiatric conditions.
At the start of treatment, the most frequent comor-
bidities (>10%) were hypertension and heart dis-
eases, metabolic disorders and joint, bone and pain
disorders. The most frequently reported psychiatric
conditions (>10%) were depression (mild or moder-
ate) and anxiety (severe depression, bipolar disorders,
psychosis and apathy were also present at a lower
frequency), with about 28% of patients assuming
antidepressants [mainly selective serotonin reuptake
inhibitors (SSRIs), serotonin–norepinephrine reup-
take inhibitors (SNRIs) and tricyclics].
Concomitant PD medications
Almost all patients (N = 1,556, 99.9%) had ≥ 1
ongoing treatment for PD at the start of safi-
namide therapy. As shown in Table 2, 1,537 patients
(98.7%) were treated with levodopa (L-dopa), 912
(58.5%) dopamine agonists, 424 (27.2%) catechol-O-
methyltransferase (COMT) inhibitors, 178 (11.4%)
amantadine, 34 (2.2%) anticholinergics and 11
(0.7%) monoamine oxidase-B (MAO-B) inhibitors
(rasagiline). Over the study period, the overall mean
dose of levodopa (alone or plus COMT inhibitors)
and the overall mean doses of the dopamine-agonist
treatments did not change significantly, confirming
what has been previously observed in the pivotal trials
[12, 13].
Table 2
Concomitant PD treatments at the start of safinamide




Dopamine agonist 912 (58.5%)
COMT inhibitors 424 (27.2%)
Amantadine 178 (11.4%)
Anticholinergics 34 (2.2%)
MAO-B inhibitors 11 (0.7%)
Percentages are computed out of the total number of patients
evaluable for FAS. A patient could have more than one PD
treatment. PD, Parkinson’s disease; FAS, Full Analysis Set; N,
number of patients; COMT, catechol-o-methyltransferase; MAO-
B, monoamine-oxidase B.
Motor fluctuations
As shown in Table 3, at start of safinamide treat-
ment 1437 (92.2%) patients had motor fluctuations,
the most frequent one being wearing off (74.3%).
The percentage of patients with motor fluctuations
decreased during the study due to safinamide treat-
ment: at 4, 8, and 12 months after start of treatment,
the percentage of patients with motor fluctuations
was respectively 73.5%, 70.6%, and 67.4%, with the
highest reduction for wearing-off and early morning
fluctuations. The improvements seen after 4 months
indicate a rapid onset of efficacy of the drug. The
percentage of patients with fluctuations has been cal-
culated at each follow-up visits based on the available
data and on the total number of the evaluable patients.
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Table 3
Fluctuations at the start of treatment with safinamide and during the follow-up
Motor complications FAS Total evaluable Total evaluable Total evaluable
(N = 1,558) patients at patients at patients at
4 months 8 months 12 months
(N = 1,373) (N = 1,323) (N = 1,326)
Any 1,437 (92.2%) 1,009 (73.5%) 934 (70.6%) 894 (67.4%)
Wearing-off 1,158 (74.3%) 752 (54.8%) 704 (53.2%) 701 (52.9%)
Early morning fluctuations 363 (23.3%) 198 (14.4%) 196 (14.8%) 182 (13.7%)
Unpredictable fluctuations 264 (16.9%) 152 (11.1%) 149 (11.3%) 133 (10.0%)
Delayed on 177 (11.4%) 108 (7.9%) 109 (8.2%) 109 (8.2%)
Dyskinesia 610 (39.2%) 469 (34.2%) 409 (30.9%) 369 (27.8%)
Other 87 (5.6%) 62 (4.5%) 52 (3.9%) 32 (2.4%)
Percentages were computed out of the number of patients evaluable for the FAS and for each follow up visit. FAS,
Full Analysis Set; N, number of patients.
Fig. 1. Adverse events and adverse reactions during observation
(overall). AE, Adverse Event; SAE, Serious Adverse Event; ADR,
Adverse Drug Reaction; SADR, Serious Adverse Drug Reaction.
Primary endpoint
Adverse events and serious adverse events
As reported in Fig. 1, during observation 714
(46%) patients experienced at least one AE and 432
(28%) patients experienced at least one ADR; 143
patients (9%) had at least one SAE and 36 patients
(2%) had at least one SADR. The percentage of
patients experiencing AEs during one year of treat-
ment with safinamide in real-life conditions was 30%
lower compared to the percentage observed in six-
months pivotal trials [12, 13].
Adverse events were mainly mild (62.0%) or mod-
erate (28.0%): only 2% were considered to have
a definite relationship with safinamide and in the
majority of the cases no action was taken regard-
ing the treatment and the outcome was resolved. The
monthly incidence rate of AEs was very low, 0.07
AEs per patient per month. In Table 4 the AEs are
classified by system organ class (SOC).
Dyskinesia was the most frequently reported
AE among nervous system disorders, although it
occurred in a lower frequency in the SYNAPSES
study compared to previous pivotal trials (13.7% vs
18%).
Other AEs with a frequency ≤ 3% of the total num-
ber of events were hallucinations (N = 41, 2.9%),
fall (N = 25, 2.3%), nausea (N = 18, 1.7%), consti-
pation (N = 14, 1.3%) and headache (N = 14, 1.3%).
The AEs observed were those already described in
the patients’ leaflet and no differences were detected
in term of nature, frequency, causal relationship or
severity.
Forty-four eye disorders (3.1% of the total number
of AEs) were observed, all non serious: the most fre-
quent ones (<1%) were blurred vision, reduced visual
acuity and diplopia. It must be noted that data on
the concomitant use of safinamide in patients with
retinopathy of any type are not available because
these subjects were not enrolled. Nevertheless, no
relevant frequency of cataract was reported thus no
signals of ophthalmological relevance were detected.
As previously reported, 194 serious adverse events
(SAEs) occurred in about 9% of patients. SAEs were
about 14% of all adverse events. The most frequently
reported SAEs by system organ class were infec-
tions and infestations (N = 38, 3.0% of all occurred
AEs), injury, poisoning and procedural complications
(N = 31, 2.0%) and nervous system disorders (N = 29,
2.0%).
Among the above, the most frequent were pneumo-
nia (N = 9), urinary tract infections (N = 6), dyskinesia
(N = 5) and femur fractures (N = 5).
The majority of SAEs was completed resolved. No
SAEs had a definite relationship with safinamide and
only eight (4.0% of all SAEs) and four (2.0% of all
SAEs) had a possible or probable relationship with
safinamide, respectively.
Patients with a partially retrospective observa-
tion period (having started treatment with safinamide
before study inclusion) were 779 (50% of evaluable
patients). No differences were detected in term of AE
or SAE frequency, based on the sensitivity analysis,
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Table 4
Distribution of adverse events severity by system organ class
System Organ Class Any Mild Moderate Severe
N = 1,435 (100%) N = 888 (62%) N = 404 (28%) N = 143 (10%)
Nervous system disorders 480 (33.4%) 345 (24.0%) 110 (7.7%) 25 (1.7%)
Psychiatric disorders 205 (14.3%) 121 (8.4%) 68 (4.7%) 16 (1.2%)
Gastrointestinal disorders 107 (7.4%) 73 (5.1%) 29 (2.0%) 5 (0.3%)
Injury, poisoning and procedural complications 99 (6.9%) 36 (2.5%) 41 (2.9%) 22 (1.5%)
Musculoskeletal and connective tissue disorders 94 (6.5%) 55 (3.8%) 37 (2.6%) 2 (0.1%)
General disorders 93 (6.5%) 65 (4.5%) 21 (1.5%) 7 (0.5%)
Infections and infestations 75 (5.2%) 32 (2.2%) 18 (1.3%) 25 (1.7%)
Eye disorders 44 (3.1%) 34 (2.4%) 10 (0.7%) 0 (0%)
Vascular disorders 37 (2.5%) 23 (1.6%) 12 (0.8%) 2 (0.1%)
Respiratory, thoracic and mediastinal disorders 32 (2.3%) 16 (1.1%) 8 (0.6%) 8 (0.6%)
Skin and subcutaneous tissue disorders 27 (1.9%) 22 (1.5%) 4 (0.3%) 1 (0.1%)
Renal and urinary disorders 26 (1.8%) 16 (1.1%) 7 (0.5%) 3 (0.2%)
Cardiac disorders 25 (1.7%) 5 (0.3%) 9 (0.6%) 11 (0.8%)
Metabolism and nutrition disorders 18 (1.2%) 12 (0.8%) 4 (0.3%) 2 (0.1%)
Investigations 12 (0.8%) 9 (0.6%) 3 (0.2%) 0 (0%)
Neoplasms benign, malignant and unspecified 12 (0.9%) 1 (0.1%) 3 (0.2%) 8 (0.6%)
Surgical and medical procedures 12 (0.8%) 3 (0.2%) 7 (0.5%) 2 (0.1%)
Ear and labyrinth disorders 11 (0.8%) 11 (0.8%) 0 (0%) 0 (0%)
Hepatobiliary disorders 7 (0.5%) 0 (0.0%) 6 (0.4%) 1 (0.1%)
Blood and lymphatic system disorders 6 (0.4%) 3 (0.2%) 2 (0.1%) 1 (0.1%)
Reproductive system and breast disorders 5 (0.4%) 3 (0.2%) 1 (0.1%) 1 (0.1%)
Endocrine disorders 2 (0.2%) 1 (0.1%) 1 (0.1%) 0 (0%)
Percentages were computed out of the total number of AEs and data sorted by descending frequency of SOC. N, number of patients.
between patients who started safinamide before or
after study inclusion.
A total of 233 (16.9%) evaluable patients had
non-appropriate use of safinamide (e.g., absence
of fluctuations, safinamide starting dosage differ-
ent from 50 mg/day, no concomitant levodopa use,
diagnosis different from idiopathic PD or concomi-
tant treatment with other MAO-B inhibitors). These
data were captured in the SYNAPSES study because
they represent the real-practice of the PD treatment.
Although not initially foreseen by the study proto-
col, a descriptive analysis on the frequency of safety
events was provided in patients undergoing appro-
priate use of safinamide vs inappropriate use: no
differences were detected between the two groups.
Secondary endpoints
Safinamide treatment patterns
Safinamide was administered at an initial dose of
50 mg/day to 94% of patients; during the observa-
tion period, 58.0% of patients had a dose increase
from 50 to 100 mg due to “clinician decision” and
6% a dose decrease from 100 to 50 mg due to
“patient choice”. Safinamide temporary discontinu-
ation was observed for 68 patients (4.4%), while 336
patients (21.6%) permanently discontinued the drug
(a similar percentage was reported in pivotal trials).
Main reasons for discontinuation were adverse events
(N = 161, 10.3%), patient choice (N = 81, 5.1%) and
disease progression (N = 20, 1.3%). No relevant
differences regarding the treatment patterns with safi-
namide emerged between the subgroup of patients
(elderly, with relevant comorbidities and with psy-
chiatric conditions).
Subgroup of patients
The summary of the safety results of the three sub-
group of interest (patients aged >75 years, patients
with relevant comorbidities and patients with psychi-
atric conditions) is shown in Fig. 2.
Elderly patients. During observation 47.3%
patients older than 75 years had at least one AE,
26.1% at least one ADR, 13.6% at least one SAE
and 2.3% at least SADR.
The proportions of patients experiencing at least
one AE, ADR or SADR were similar in the popula-
tion of patients aged >75 compared to patients aged
≤75, while was higher for SAE in patients aged >75
(13.6%) compared to patients aged ≤75 (7.7%). No
relevant differences emerged in severity, causal rela-
tionship or action taken between the two age groups.
Dyskinesia was still the most frequent AE in elderly
patients, but with a lower frequency than the overall
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Fig. 2. Safety summary in subgroups of patients. AE, Adverse Event; SAE, Serious Adverse Event.
sample and the younger patients (9.5% vs 13.7%)
while hallucinations (5.1% vs 2.9%) were slightly
more frequent in patients aged >75.
Patients with comorbidities. During observation
49.1% patients with relevant comorbidities had at
least one AE, 28.6% had at least one ADR, 11.1%
had at least one SAE and 2.5% at least one SADR.
The proportion of patients with AEs and SAEs was
higher in patients with relevant comorbidities than in
patients without (49.1% vs 37.8% and 11.1% vs 4.6%
respectively). No other differences were detected.
Dyskinesia was the most frequent AE in the sub-
group of patients with comorbidities, with a slightly
lower frequency than the overall sample and the
patients without comorbidities (12.3% vs 13.7%).
The distribution of the occurrence of the other AEs
was similar in the two subgroup of patients (with and
without comorbidities) and the overall sample.
Patients with psychiatric conditions. During obser-
vation, 47.8% patients with psychiatric conditions
had at least one AE, 31.0% at least one ADR, 10.3%
at least one SAE and 3.5% at least one SADR.
No relevant differences were observed in patients
with or without psychiatric conditions regarding the
severity, causal relationship and action taken for
adverse events. No serotoninergic syndromes were
reported despite 28% of patients were assuming
antidepressant drugs including fluoxetine, thus con-
firming that the concomitant use of safinamide and
SSRIs/SNRIs/tricyclics is safe and well tolerated.
Dyskinesia was the most frequent AE in the sub-
group of patients with psychiatric conditions, with a
slightly higher frequency than in the overall sample
and in patients without psychiatric conditions (15.6%
vs 13.7%).
UPDRS scores
The mean (SD) of UPDRS (part I, II, III, IV, total)
scores at the beginning of treatment with safinamide
and at 4-, 8-, 12-month follow up are shown in Fig. 3.
A substantial stability of disease severity over time
emerged with improvements since the first 4-month
follow-up in the UPDRS part II (Activities of Daily
Living) part III (Motor Examination), part IV (Com-
plication of Therapy) and UPDRS Total Score.
According to the criteria developed by Shulman
[14], a difference >4.3 points for the UPDRS Total
score (subscales I, II, III and IV) and >2.5 points for
the UPDRS Part III (Motor Examination score) is
considered clinically significant. The percentage of
patients with clinically relevant differences between
baseline and 12-month follow up visit is reported
in Fig. 4. After one-year treatment with safinamide,
39% and 45% patients showed a clinically significant
improvement in UPDRS Total and Motor Examina-
tion scores, respectively.
DISCUSSION
The SYNAPSES study documented for the first
time the real-world use of safinamide in six European
countries, particularly in patients’ populations such
as patients older than 75, with psychiatric illnesses
or with relevant comorbidities, where limited infor-
mation was available in the pre-authorization clinical
trials. The results have been analyzed and presented
as pooled data of the two safinamide doses, anyway
during the study 58% of patients increased the dose
of safinamide from 50 to 100 mg with no differences
in term of adverse events, including dyskinesia, con-
firming what has been reported in the literature.
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Fig. 3. UPDRS (part I, II, III, IV, total scores) at start of treatment with safinamide and at 4-, 8-, and 12-month follow-up (overall). UPDRS,
Unified Parkinson’s Disease Rating Scale.
Fig. 4. Percentage of patients with clinically important differ-
ence (improvement) in the UPDRS scores (difference between
12-months follow-up and baseline). UPDRS, Unified Parkinson’s
Disease Rating Scale.
Safinamide was safe and well tolerated and no
major or unexpected safety concerns were identi-
fied. The percentage of patients experiencing AEs
was 30% lower compared to the percentage observed
in previous pivotal trials. This is remarkable because
pivotal trials have strict inclusion/exclusion criteria
and enroll generally patients with less comorbidities
than subjects in a practice setting.
The rate of AEs observed with safinamide was also
50% lower than the percentage reported in the same
patients’ population for rasagiline in the PRESTO
study (45.7% vs 93% respectively) [15] and 40%
lower than the percentage reported for opicapone in
the OPIPARK study (45.7% vs 74.9% respectively)
[16].
The most frequent reported AE was dyskinesia, as
expected with drugs that increase levodopa bioavail-
ability [17], although at very lower frequency than
those observed in previous pivotal clinical trials.
However, it is important to note that most PD patients
who complained of dyskinesia have presented these
abnormal movements since the beginning of the study
with no further aggravation.
The treatment with safinamide did not require
any change in the concomitant dopaminergic ther-
apies, allowing a better motor control with no
safety problems. Despite its dopaminergic activity,
impulse control disorder or sleep deterioration were
not reported after safinamide treatment. Safinamide
increases dopamine levels in the putamen, the region
devoted to motor control, but does not affect regions
involved in reward circuitry and impulse control
disorders (ICDs) such as the nucleus accumbens
[18]. Moreover, glutamate levels seem to mediate
reward-seeking behavior within this nucleus [19].
Safinamide is a MAO-B inhibitor and a glutamate
modulator and this second mechanism of action,
in addition to the non-influence on the mesolimbic
structures, may contribute to avoid any ICD deterio-
ration.
At the start of the study about 60% of the patients
were receiving dopamine agonists (DA) as concomi-
tant treatment with L-dopa. It is reported in the
literature that 15% to 20% of patients on DA exhibit
impulse control disorder behavior (e.g., gambling
and hypersexuality), imposing a significant economic
burden and a quality of life deterioration of patients
and their caregivers [20]. The adjunct of safinamide
improved the symptoms without tolerability prob-
lems and with no need to increase the DA dose or
switch to another drug.
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Regarding sleep disorders, it is known that dopa-
mine agonists alone or combined with levodopa can
cause sleep disturbances and episodes of sudden sleep
attacks [21]. Glutamate is an important wake-active
neurotransmitter producing a sustained behavioral
and electro-encephalogram arousal [22]. The absence
of sleep disturbances in PD patients taking safinamide
may be related to the effects of the drug on the glu-
tamatergic system.
The safety profile of safinamide in patients over 75
years, with comorbidities and with psychiatric con-
ditions appeared to be broadly similar to the overall
population. The slightly higher percentage of SAEs
observed in elderly patients and in patients with
comorbidities is an expected phenomenon since they
are generally affected by several relevant concomi-
tant pathologies treated with polytherapies. This is
confirmed by the fact that ADRs did not occur more
frequently in these patients, suggesting that there
were no contraindications to the use of safinamide
in these subjects. Safinamide in fact, unlikely rasag-
iline, is not metabolized by CYP1A2 and thus does
not have any important drug-drug interaction. The
slightly higher frequency of hallucinations in elderly
patients reflects, as known, age as risk factor for hal-
lucinations [23].
The absence of any safety issue in psychiatric
patients, despite their concomitant treatment with
antidepressant drugs, suggests that safinamide does
not require special safety precautions for these sub-
jects. Safinamide, in fact, increases the synaptic
availability of dopamine without a direct interaction
with dopamine D2 receptors that are known to be
involved in psychotic behaviors [18].
Motor fluctuations, and in particular wearing-off
and early morning fluctuations, affect the majority of
patients with PD: as observed in the DEEP study,
63–75.6% of patients treated with L-dopa experi-
enced wearing-off with a significant deterioration of
their quality of life [24]. The pharmacological treat-
ment of motor fluctuations is difficult and remain a
real unmet need [25]. There is a significant associa-
tion between motor fluctuations and annual costs of
PD: the mean costs of patients with motor fluctuations
is generally two-three times greater than the costs
of patients without [26]. Treatment strategies capa-
ble of delaying the onset or attenuating the severity
of motor fluctuations could be expected to improve
QoL and reduce some of the economic burden of PD.
Safinamide was shown to reduce of about 40–50%
motor fluctuations, in particular wearing-off and early
morning fluctuations, with visible efficacy already at
4 months. This significant and rapid-onset effect of
safinamide may be explained by its dual mechanism
of action, dopaminergic and glutamatergic [27]. The
pathogenesis of motor fluctuations, in fact, suggests
that glutamate and other neurotransmitters, in addi-
tion to dopamine, contribute to the appearance of the
symptoms [28].
Consistent with the benefits observed in motor fluc-
tuations, UPDRS scores improved with safinamide
as adjunct therapy after only 4 months of treatment
with a clinically important effect in ≥40% of patients
according to the criteria developed by Shulman et al.
[14]. In term of absolute values, the magnitude of the
effect of safinamide on motor symptoms is similar
to that reported for other MAO-B inhibitors and for
COMT inhibitors by Stowe et al. [29]. As expected,
the improvements are higher at 4 and 8 months due
to the progression of the pathology, nevertheless the
results obtained for the motor score are noteworthy
because the patients were already receiving an opti-
mized dopaminergic therapy (based on clinician’s
judgement) and further improvements were unex-
pected. The annual decline in early untreated PD
patients is 5–6 points for UPDRS III motor score [30].
Dopaminergic therapies reduce the decline in motor
function to an annual downfall of 3.3 points [31]. The
add-on of safinamide to a standard levodopa therapy
compensates this progressive deterioration in 45% of
patients allowing for a substantial stability of their
motor symptoms.
The main strengths of this study are the large num-
ber of fluctuating patients included, with a broad
range of disease severity (Hoehn and Yahr stages
I–IV), the real-life clinical practice setting and the
relevant sample sizes for the subgroups of interest.
Limitations include the open-label design without a
placebo or active control, typical of the observational
studies, where the expectations of the patients are
generally higher than in double-blind trials. Patients
diaries for ON and OFF time were not adopted, as
suggested by EMA, because they are not used in rou-
tine clinical practice. There was also a potential risk of
under-estimation of AEs from both the patients and
the clinicians: however, no relevant difference was
observed when considering the frequency of AEs or
SAEs in retrospective or prospective patients.
Conclusions
The management of motor complications in PD
remains a significant challenge in which all available
pharmacologic options involve a risk of exacerbating
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adverse events. The SYNAPSES study, conducted in
a real word setting in six European countries, con-
firmed the safety and tolerability of safinamide, as
adjunct therapy, in fluctuating patients and in spe-
cial groups of subjects. Neither age, comorbidities,
nor psychiatric conditions seem to have any relevant
effect on its safety profile.
Motor complications and motor scores improved
with clinically significant results in the UPDRS scale
maintained in the long-term. These results suggest
that safinamide can be an effective and safe option for
the management of motor fluctuations in levodopa-
treated patients.
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